Paul A. Grayson - Nov 15, 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role: Director
Signature: /s/ Kaitlyn Arsenault, as Attorney-in-Fact
Stock symbol: SKYE
Transactions as of: Nov 15, 2024
Transactions value $: -$432,061
Form type: 4
Date filed: 11/19/2024, 09:14 PM
Previous filing: Oct 30, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SKYE	Common Stock	Sale	-$1.7K	-307	-0.09%	$5.55	346K	Nov 15, 2024	Direct	F1
transaction	SKYE	Common Stock	Sale	-$430K	-86.2K	-24.93%	$4.99	260K	Nov 18, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax obligations in connection with the vesting and settlement of performance-based restricted stock units.
F2	The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.

Content

The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax obligations in connection with the vesting and settlement of performance-based restricted stock units.

The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.